1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
EV Biologics, Inc.

EV Biologics, Inc.

YECO
EV Biologics, Inc.US flagOther OTC
0.00
USD
- -
- -
2,890.00Market Cap
EV Biologics, Inc.
YECO
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
TTM
FRC
17.89
18.73
28.89
17.88
3.95
35.34
Revenue per Share
4.23
4.5
5.42
-22.3
-3.08
-65.32
Basic EPS, GAAP
-1.16
4.7
2.61
-9.79
-0.16
-18.75
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
1.14
5.35
13.26
-13.4
-16.35
-21.06
Book Value per Share
10.26
14.83
26.09
3.82
0.69
2.26
Tangible Book Value per Share
2
2
2
2
2
2
Basic Weighted Avg Shares
42
44
46
43
10
62
Sales/Revenue/Turnover
33.23
34.23
27.81
7.47
-41.34
-4.1
Operating Margin (%)
1
1
2
2
1
2
Depreciation Expense
10
11
9
-53
-7
-115
Net Income, GAAP
22.44
23.36
25.03
- -
- -
24.16
Effective Tax Rate (%)
23.66
24.05
18.77
-124.73
-78.15
-184.87
Profit Margin (%)
1
13
-4
-14
-21
-19
Working Capital
1
- -
- -
- -
- -
- -
LT Debt
27
38
47
11
4
6
Total Equity
- -
26.88
17.74
- -
- -
15.52
Return on Invested Capital (%)
- -
65.02
34.43
- -
- -
30.6
Return on Capital (%)
- -
138.94
51.18
- -
- -
44.38
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'16
Sep'17
Dec'17
ST Debt
10
10
9
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
4
6
2

Working Capital

FRC

•

in mil. unless spec.
Jun'16
Sep'17
Dec'17
Total Current Assets
11
10
9
Cash, Cash Equivalents & STI
3
3
2
Accounts Receivable, Net
6
5
5
Inventories
- -
1
- -
Total Current Liabilities
25
28
28
Payables & Accruals
13
13
14
ST Debt
10
10
9
Deferred Revenue
3
4
5

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-66.99%
Free Cash Flow
- -
- -
-98.38%
Net Income, GAAP
- -
- -
-86.03%
Sales/Revenue/Turnover
- -
- -
-77.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
13
13
11
5
43
2017
3
43
- -
- -
10
2018
39
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
1.51
0.88
1.06
- -
-22.3
2017
-1.18
-111.49
- -
- -
-3.08
2018
-0.93
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
Similar Companies
Shanghai Henlius Biotech, Inc. (2696.HK)
GC Corp. (005250.KS)
Thalia Therapeutics Plc (THAT.L)
Turning Point Therapeutics, Inc. (TPTX)
Organovo Holdings, Inc. (ONVO)
Passage Bio, Inc. (PASG)
Business
Yulong Eco-Materials Limited (YECO) is an investment holding company primarily engaged in the manufacture and sale of eco-friendly building products in China. The company operates through three main segments: the Yulong Bricks segment, which produces and sells fly-ash bricks; the Yulong Concrete and Yulong Transport segment, which produces and sells ready-mixed concrete; and the Yulong Renewable segment, which handles hauling and processing of construction waste along with production and sales of recycled aggregates and recycled bricks. Incorporated in 2011 and headquartered at the Eastern End of Xiwuzhuang Village, Jiaodian Town, Xinhua Area, Pingdingshan, Henan Province, China, Yulong employs 259 people and focuses on vertically integrated operations in the construction materials industry, primarily serving regional markets in and around Pingdingshan and Henan Province. Recent developments include the operational launch of a state-of-the-art recycling plant and brick plant with two production lines since April 2015, establishment of a research and development center for new eco-friendly products, acquisition of an exclusive hauling license through 2032 for construction waste in Pingdingshan's built-up area, expansion of its truck fleet from 50 to 120 units, and commencement of waste hauling and recycling operations in August 2015 for a high-speed railway project in Shangqiu, Henan Province, generating over 1.3 million metric tons of waste. The company reported trailing twelve-month revenue of $5.67 million and net income of $40.68 million as of the latest available data.

Company News

APIChatGPT

  • defenseworld.net

    United States Lime & Minerals (NASDAQ:USLM) and Yulong Eco-Materials (OTCMKTS:YECO) Critical Contrast

  • defenseworld.net

    Smith-Midland (NASDAQ:SMID) and Yulong Eco-Materials (OTCMKTS:YECO) Critical Review

  • accesswire.com

    EV Biologics Updates on Funding and Sales

  • accesswire.com

    EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic

  • accesswire.com

    EV Biologics Appoints Senior Investment Banker as Corporate Finance Director

  • accesswire.com

    EV Biologics Hires Senior Chief Financial Officer

  • accesswire.com

    EV Biologics Updates on NFT Minting

  • accesswire.com

    EV Biologics Updates on NFT Warrant Dividend Distribution

  • accesswire.com

    EV Biologics Briefs Shareholders on Market Cap Peer Comparison

  • accesswire.com

    EV Biologics NFT Dividend Information

  • accesswire.com

    EV Biologics NFT Dividend Warrant Date

  • accesswire.com

    EV Biologics Starts Custom Cell Isolation with Lonza Cell Bio Services

  • accesswire.com

    EV Biologics Unveils NFT Dividend Warrant

  • accesswire.com

    EV Biologics Signs LOI with Lonza Cell & Gene Therapy

  • accesswire.com

    EV Biologics Confirms Funding to Commence Cell Line Generation & Advance Exosome Research